Mitsui & Co. Invests Additional $CDN25 Million in BioAmber Sarnia
Feb 10, 2016
MONTREAL, Febr. 10, 2016 /CNW Telbec/ - BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, is pleased to announce that Mitsui & Co. Ltd., its partner in the Sarnia bio-based succinic acid plant, is investing an additional CDN$25 million in the joint venture for 10% of the equity, increasing its stake from 30% to 40%. Mitsui will also play a stronger role in the commercialization of bio-succinic acid produced in Sarnia, providing dedicated resources alongside BioAmber's commercial team. BioAmber will maintain a 60% controlling stake in the joint venture.
"Mitsui is continuously committed to renewable chemistry and through our increased equity stake we will be more actively involved in joint venture management and sales, leveraging our global sales platforms," said Hidebumi Kasuga, General Manager, Specialty Chemicals Division, Basic Chemicals Business Unit. "We are very happy with Sarnia's fermentation and plant operations performance to date and the JV has received quality certifications from more than 90 customers. With this progress, I am confident that Sarnia's bio-succinic acid will be penetrating the global marketplace quickly."
"Mitsui's increased commitment to the Sarnia plant is a strong endorsement of its value and potential. We have in Mitsui a financially robust, global partner that is motivated by Sarnia's progress and prospects," said Jean-Francois Huc, CEO of BioAmber. "This investment strengthens Sarnia's balance sheet as we ramp up production and sales."
BioAmber (NYSE: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products. For more information visit www.bio-amber.com
About Mitsui & Co.
Mitsui is one of the most diversified and comprehensive trading, investment, and service enterprises in the world, with 140 offices in 66 countries as of November, 2015. Utilizing our global operating locations, network and information resources, we are multilaterally pursuing business that ranges from product sales, worldwide logistics and financing, through to the development of major international infrastructure and other projects in the following fields: Iron & steel products, mineral & metal resources, infrastructure projects, integrated transportation systems, chemicals, energy, food resources, food products & services, consumer services, IT & communication, and corporate development business. Mitsui is actively taking on challenges for global business innovation around the world. For more information, visit http://www.mitsui.com.
This press release contains forward-looking statements. All statements other than statements of historical fact in this press release are forward-looking statements. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond BioAmber's control. BioAmber's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For additional disclosure regarding these and other risks faced by BioAmber, see disclosures contained in BioAmber's public filings with the SEC including, the "Risk Factors" section of BioAmber's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the Quarter ended September 30, 2015.
SOURCE BioAmber Inc.
For further information: BioAmber Investor Contact : Mike Hartmann, Executive Vice President, BioAmber Inc., (514) 844-8000 extension 120, email@example.com